Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle
challenging protein targets deemed undruggable with traditional small molecule inhibitors …

Therapeutic monoclonal antibodies targeting immune checkpoints (ICPs) have changed the
treatment landscape of many tumors. However, response rate remains relatively low in most …

The past decade of cancer research has been marked by a growing appreciation of the role
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …

In this Timeline, we describe the characteristics of tumour antigens that are recognized by
spontaneous T cell responses in cancer patients and the paths that led to their identification …

Genome-wide transcriptome analyses are routinely used to monitor tissue-, disease-and cell
type–specific gene expression, but it has been technically challenging to generate …

AMP-activated protein kinase (AMPK) is a master sensor and regulator of cellular energy
status. Upon metabolic stress, AMPK suppresses anabolic and promotes catabolic …

Abstract Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes
(TILs) is currently applied in several centers. Robust and remarkably consistent overall …

Abstract Cancer/testis (CT) antigens, of which more than 40 have now been identified, are
encoded by genes that are normally expressed only in the human germ line, but are also …

With the recent developments of adoptive T cell therapies and the use of new monoclonal
antibodies against the immune checkpoints, immunotherapy is at a turning point. Key …

The melanoma antigen (MAGE) family consists of more than 60 genes, many of which are
cancer-testis antigens that are highly expressed in cancer and play a critical role in …